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38 Objectives: Trial data have provided an evidence base to guide early treatment in rheumatoid 
39 
40 
41 arthritis (RA). Few studies have investigated rheumatologists’ adherence to guidelines, and 
42 
43 subsequent impact on outcomes. The objectives of this study are to characterise baseline 
44 
45 prescribing for patients with RA across the National Health Service, identifying treatment 
47 
48 decisions that associate with patient outcomes. 
49 
50 
51 Methods: A nationwide audit of RA collected information on treatment choices, disease 
52 
53 activity scores, and sociodemographic factors at baseline. Treatment response was assessed 
55 
56 at three months. Multilevel regression models were used to characterise departmental 
57 
58 variations in prescribing. Heat maps were used to visualise geographical variation. Mixed 
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3 effects regression models were constructed to assess the relationship between treatment 
4 
5 
6 decisions  and  disease  outcomes,  adjusting  for  patient  and  department  level covariates. 
7 
8 Results: a total of 7,154 patients with a diagnosis of RA were recruited from 136 departments. 
9 
10 
11 There was broad variation in prescribing choices, even between departments near one 
12 
13 another, with evidence of substantial deviation from guidelines. Over 75% of patients 
14 
15 
received glucocorticoids, fewer than half received combination conventional disease 
17 
18 modifying antirheumatic drugs. Early glucocorticoid therapy associated with achieving a good 
19 
20 treatment response, odds ratio 1.93 (95% confidence interval 1.31 to 2.84, p value 0.001). 
22 
23 The association was maintained following propensity modelling and imputation. 
24 
25 
26 Conclusion: Guideline adherence varies between departments and cannot be explained by 
27 
28 case-mix alone. Departments that prescribe early adjunctive steroid achieve better short- 
30 
31 term outcomes. Further research should work to ensure that the early arthritis evidence base 
32 









42 Rheumatology key messages 
44 
1. This study is the first to characterise early RA national treatment variations between 
46 departments. 
47 2. Early RA treatment decisions predict patient outcomes as early as three months after 
48 diagnosis. 
50 3. Treating RA according to guidelines varies, improving compliance is an efficient 
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7 Trial  data  support  prompt  commencement  of  therapy  in  newly  diagnosed  rheumatoid 
8 
9 arthritis (RA)(1). This has led to the widespread adoption of a ‘treat to target’ approach with 
10 
11 
12 aggressive escalation of therapy in the first three months following diagnosis. The initial drug 
13 
14 strategy may involve one or more conventional disease modifying antirheumatic drug 
15 
16 
17 (cDMARD), with or without glucocorticoids. Clinician preference and comfort with certain 
18 
19 medications continue to be key in therapy selection(2). European and American guidelines 
20 
21 
for newly diagnosed RA recommend(3-5): 
23 
24 
 First line treatment with a cDMARD preferably methotrexate, with dose escalation; 
26 
27  Consideration of short-term bridging glucocorticoids, and; 
28 
29 
 Combination disease modifying treatment if treatment target is not achieved despite 
31 
32 dose escalation. 
33 
34 
35 Previous guidance advocated combination cDMARD therapy and glucocorticoids as first line 
36 
37 
38 therapy. A review of the trial data comparing cDMARD monotherapy to combination therapy 
39 
40 showed inconsistent evidence of benefit in terms of disease activity, patient reported 
41 
42 
outcomes, or adverse events, from adding a second disease modifying therapy at baseline(6). 
44 
45 
46 The shift in emphasis away from recommending glucocorticoids in all patients at baseline was 
47 
48 driven by a review of trial data that identified a single study(7) which was found to have a 
49 
50 
substantial risk of bias(8). It was concluded that further evidence was required to assess if 
52 
53 glucocorticoids are beneficial in early RA. A further review of four trials reported 
54 
55 improvements in disease activity, but with a high risk of bias and a lack of statistical power to 
56 
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3 meet primary endpoints. The authors concluded that combining glucocorticoid therapy and 
4 
5 
6 cDMARDs may be beneficial(6). 
7 
8 
9 Trial data have given an inconsistent picture of the most efficacious pharmacologic approach 
10 
11 in early RA. Consequently, guidelines allow treating physicians flexibility in their initial 
12 
13 
14 treatment approaches. This inevitably leads to variation in therapy choices. Large 
15 
16 observational prospective cohorts offer an opportunity to assess the degree of prescribing 
17 
18 






25 Here we will utilise a large national early RA cohort to characterise cDMARD and 
26 
27 glucocorticoid prescribing patterns across England and Wales, and identify treatment 
28 
29 










The first National clinical audit of early inflammatory arthritis (EIA) ran from early 2014 to late 
41 
42 2015 across England and Wales. During this time, UK guidelines advocated treatment 
43 




Adult patients presenting with symptoms consistent with RA were eligible for inclusion. This 
49 
50 included any patient with a new onset of inflammatory arthritis >six weeks duration and 
51 
52 either a positive rheumatoid factor (RF) or anti-cyclic citrullinated protein (anti-CCP) antibody 
53 
54 
55 or a swollen joint count ≥five. 
56 
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3 All rheumatology departments were required to participate. Information was collected via 
4 
5 
6 physician and patient questionnaires at the initial rheumatology appointment. Demographic 
7 
8 information was collected including age, gender, smoking status, ethnicity, work status, and 
9 
10 
11 partial patient postcode. Clinical information collected included time to referral, 
12 
13 rheumatology review, treatment initiation including therapy choices, and if the referral letter 
14 
15 
suggested a diagnosis of EIA. Laboratory investigations including anti-CCP antibody status, RF 
17 
18 antibody status, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were 
19 
20 recorded. Examination findings including tender and swollen joint counts and a patient 
22 
23 reported visual analogue scale of global health were also collected. A proxy rank of the index 
24 
25 of multiple deprivation (IMD), a composite measure of socioeconomic position (SEP), was 
26 
27 
28 calculated from partial patient postcodes by identifying all lower super output areas (LSOAs) 
29 
30 covered by each postcode. The corresponding IMD scores were then averaged for each 
31 
32 
33 patient, allowing calculation of a ranking of SEP across the cohort. 
34 
35 
36 The disease activity score (DAS-28) is a validated measure of RA disease activity that is widely 
37 
38 used to assess response to treatment(9). It incorporates the tender and swollen joint counts, 
39 
40 
41 a patient reported global health and either ESR or CRP to provide a score of disease activity 
42 
43 ranging from 0 to 10, with a higher score indicating greater severity. The European League 
44 
45 
Against Rheumatism (EULAR) has developed a DAS-28 response criteria, stratifying patients 
47 
48 as having achieved a good, moderate or no response to therapy(10). 
49 
50 
51 Those with a diagnosis of RA had a DAS-28 score calculated at baseline and three months 
52 
53 
follow up. The scores were used to identify if patients had achieved a good EULAR DAS-28 
55 
56 response to therapy at three months follow up. 
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3 Patient and Public Involvement 
4 
5 
6 A patient representative was engaged and consulted in the design and delivery of the national 
8 
9 audit project. Approval to conduct research using these National Clinical Audit data was 
10 
11 obtained from HQIP. No informed patient consent was required, as this dataset was created 
12 
13 
14 from routinely collected data during clinical practice. 
15 
16 
17 Statistical analysis 
18 
19 
20 Baseline and demographic variables, including prescribing patterns, were described using 
21 
22 summary statistics, assessing differences between two treatment response groups at three 
24 
25 months follow up: (1) patients that achieved a good EULAR DAS-28 response, and; (2) patients 
26 
27 that achieved moderate or no EULAR DAS-28 response. Frequencies and patterns of missing 
28 
29 
30 data were assessed and tabulated. 
31 
32 
33 Variation in prescribing 
34 
35 
36 To characterise departmental variations in prescribing, mixed-effects logistic regression 
37 
38 models were constructed with department included as a random effect. The random effect 
40 
41 can be considered as capturing the difference between the department mean and the overall 
42 
43 mean for the sample, allowing for the estimate of case-mix adjusted rates. Departmental 
44 
45 
46 effects on the proportion of patients prescribed glucocorticoids, methotrexate, and 
47 
48 combination cDMARD therapy were plotted on three separate caterpillar graphs. 
49 
50 
51 In order to provide a geographical picture of prescribing variation, departmental prescribing 
52 
53 
54 of glucocorticoids, methotrexate and combination cDMARDs were presented in heatmaps by 
55 
56 linking the national audit dataset to longitude and latitude coordinates data. Mapping was 
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3 performed using the grmap software package, an update of the spmap program developed in 
4 
5 






12 Treatment decisions and disease outcome 
13 
14 
15 Three mixed effects logistic regression models were constructed to assess the relationship 
16 
17 
between baseline treatment decisions and disease activity at three months follow up: 
19 
20 
21 Model 1. cDMARD combination therapy vs cDMARD monotherapy as a predictor of achieving 
22 
23 a good EULAR DAS-28 response; 
24 
25 
26 Model 2. Methotrexate therapy vs no methotrexate therapy as a predictor of achieving a 
27 
28 
29 good EULAR DAS-28 response, and; 
30 
31 
32 Model 3. Glucocorticoid therapy vs no glucocorticoid therapy as a predictor of achieving a 
33 
34 good EULAR DAS-28 response. 
35 
36 
37 The three models contain overlapping groups and are designed to test three distinct 
38 
39 
40 hypotheses, rather than to compare between models. Covariate selection across the three 
41 
42 models was determined a priori. The models were run unadjusted initially. They were then 
43 
44 
45 repeated with adjustment for: age; gender; ethnicity; smoking status; proxy IMD quintile; 
46 
47 work status; symptom duration; autoimmune antibody status; referral time; rheumatologist 
48 
49 
review time. A propensity score weighted estimate was also calculated for each model to 
51 
52 account for confounding by indication. Further details of this can be found in the 
53 
54 supplementary material, section Propensity modelling, supplementary tables S1A, S1B, and 
55 
56 
57 S1C, available at Rheumatology online). The department where rheumatology care took place 
58 
59 was included in all the models as a random effect. Incomplete data were handled by two 
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3 approaches, repeated for all three models: (1) non-responder imputation (NRI), whereby 
4 
5 
6 those with insufficient data to calculate a EULAR DAS-28 disease response were assumed  to 
7 
8 have not achieved a good response, and; multiple imputation (MI) using iterative chained 
9 
10 
11 equations with 20 cycles to impute incomplete confounder, predictor, and outcome variables. 
12 






20 Between February 2014 and October 2015, 7,154 patients with a diagnosis of RA were 
21 
22 recruited to the National Clinical Audit from across England and Wales. Table 1 details 
23 
24 
25 baseline and demographic characteristics including prescribing choices and proportions of 
26 
27 missing data. 2,256 (32%) had sufficient information at baseline and three months follow up 
28 
29 
to allow calculation of a EULAR DAS-28 treatment response. The mean DAS-28 score remained 
31 
32 moderately elevated at 3 months follow up, with a mean of 3.5 (SD 1.5). 
33 
34 
35 Table 2 details baseline and demographic characteristics stratified by EULAR DAS-28 
36 
37 
response. There were a lower proportion of females, a lower median symptom duration, and 
39 
40 a higher proportion of patients reviewed by a rheumatologist within 21 days of referral in the 
41 
42 good treatment response group. Demographic differences between those with and without 
43 
44 





50 Variation in prescribing 
51 
52 
53 Median Departmental prescribing of glucocorticoids was 83% (Interquartile range (IQR) 73% 
55 
56 to 89%) of patients seen. Combination cDMARD median prescribing proportion was 36% (IQR 
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3 19% to 57%), while methotrexate departmental median prescribing proportion was 77% (IQR 
4 
5 
6 66% to 88%). 
7 
8 
9 Figure 1 shows the variation in the baseline prescribing of: (a) combination cDMARDs; (b) 
10 
11 inclusion of methotrexate as a first line agent, and; (c) glucocorticoids. The figure displays 
12 
13 
14 adjusted point estimates with confidence intervals. Where the confidence interval boundaries 
15 
16 do not cross the horizontal mean bar, this is evidence of clinically significant variation in 
17 
18 
19 practice not explained by patient characteristics. There was variation in practice in all 
20 
21 prescribing characteristics assessed. The magnitude of variation is greatest in the prescribing 
22 
23 
of combination cDMARDs between the departments included. 
25 
26 
27 Prescribing variations are presented as heat maps in figure 2. There was broad variation 
28 
29 across geographic regions. In general, there was marked variation identified even within close 
30 
31 
geographical areas. For example, there were striking prescribing differences between 
33 
34 departments within Greater London. 
35 
36 
37 Treatment decisions and disease outcome 
38 
39 
40 Adjusted mixed effects logistic regression models showed an association between baseline 
41 
42 
43 glucocorticoids and achieving a good EULAR DAS-28 response at three months follow up, with 
44 
45 an odds ratio of 1.93 (95% confidence interval 1.31 to 2.84, p value 0.001). Neither 
46 
47 
combination cDMARD therapy (versus monotherapy) nor methotrexate (versus non- 
49 
50 methotrexate cDMARD strategies) predicted a good EULAR DAS-28 response. Odds ratios and 
51 
52 confidence intervals are detailed in table 3. The propensity score weighted estimates were 
53 
54 
55 similar to the fully adjusted models, with a small strengthening of the association between 
56 
57 baseline glucocorticoids and a good EULAR DAS-28 response (odds ratio 2.02, 95% confidence 
58 
59 
60 interval 1.31 to 3.11). The results were consistent when analyses were repeated in propensity 
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3 weighted and imputation models (see table 3 and Supplementary Table S3, available at 
4 
5 











18 This analysis has characterised prescribing patterns across England and Wales using a national 
19 
20 prospective cohort. In comparison with other cohorts disease activity at three months was 
21 
22 
23 high, with a mean DAS-28 of 3.5 at follow up, compared to 3 month DAS-28 scores of 2.2 in a 
24 
25 Scandinavian cohort (12). The observed difference in disease severity may be due to 
26 
27 
variations in sociodemographic and ethnic mix of sample populations, and/or local guidelines 
29 
30 placing a greater emphasis on early intra-articular glucocorticoid administration for swollen 
31 
32 joints, which has been shown to associate with improved outcomes (13). The UK guidelines 
33 
34 
35 in contrast suggest that short course bridging glucocorticoids should be considered to control 
36 
37 disease activity but does not discuss route of administration. 
38 
39 
40 There were substantial differences in prescribing rates of glucocorticoids, combination 
41 
42 
43 cDMARDs, and methotrexate between departments. This is consistent with previous work on 
44 
45 cDMARD UK prescribing patterns(14, 15). 
46 
47 
48 The adjusted models suggest that this high degree of variation cannot be explained by local 
49 
50 
51 differences in patient factors such as SEP, or departmental factors such as staffing levels. It is 
52 
53 more likely that the observed variation is due to clinician preferences driven by a lack of 
54 
55 
56 agreement from clinical trial data on the most efficacious treatment approach. 
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3 The heat maps indicated that there was no clear geographical pattern in prescribing decisions. 
4 
5 
6 Nearby departments often displayed disparate clinical behaviours. This reinforces the view 
7 
8 that clinician preference is the main driver behind the observed variation. Vast efforts and 
9 
10 
11 resource are invested globally in the creation of evidence-based guidelines. Guidelines for 
12 
13 prescribing in early RA currently advocate initial cDMARD monotherapy with consideration of 
14 
15 
glucocorticoids, and escalation to combination cDMARD therapy if disease control is not 
17 
18 achieved. It should be noted that at the time of data collection UK guidelines recommended 
19 
20 combination cDMARD therapy at baseline(3). Under 40% of patients received combination 
22 
23 cDMARDs in line with the old guidance. The level of variation presented here in newly 
24 
25 diagnosed RA is substantial. It is unlikely that this observation is unique to England and 
26 
27 
28 Wales(16-18). As a community, rheumatologists need to find consensus on the value of 
29 
30 guideline compliance, and how can they best disseminate the information and improve 
31 
32 
33 uptake amongst colleagues. 
34 
35 
36 Glucocorticoid use at baseline associated with achieving a good disease outcome at 3 months 
37 
38 follow up in a mixed effects logistic regression model with extensive adjustment for 
39 
40 
41 confounding. This is consistent with trial data(18-20) and supports the role of glucocorticoids 
42 
43 at diagnosis in RA to achieve low disease activity as rapidly as possible. The efficacy of 
44 
45 
glucocorticoids must be balanced with their associated side effects. Combined trial data 
47 
48 suggest low dose or short term glucocorticoid use leads to few adverse events, whereas 
49 
50 observational studies suggest associations between low dose glucocorticoids and 
51 
52 
53 cardiovascular disease, infection, and osteoporosis(21). Adverse event information was not 
54 
55 collected as part of this study, so its impact on the findings here cannot be assessed. In 
56 
57 
58 contrast to glucocorticoids, there was no association between inclusion of methotrexate in 
59 
60 the initial treatment strategy or combination cDMARD therapy and a good disease outcome. 
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3 This is consistent with the lack of consensus reported in trial data(6). An important caveat  is 
4 
5 
6 that the data included here are limited to three months follow up, which may be too short to 
7 
8 capture the effect of slower acting therapies. Furthermore, trial data support the role of 
9 
10 
11 cDMARDs in combination with biologic DMARD therapy, particularly methotrexate(22). This 
12 
13 could not be assessed here due to the length of follow up. 
14 
15 
16 This is an observational study so causality cannot be inferred from the findings. The results 
17 
18 
19 represent a picture of ‘real world’ prescribing practices and their impact on heterogenous 
20 
21 populations, outside the controlled conditions found in clinical trials. The associations 
22 
23 
remained statistically significant even after adjustment for confounders. A limitation of this 
25 
26 study is that follow up was only captured to three months, with no data collected on 
27 
28 comorbidities. cDMARDs typically require two to three months of therapy before 
30 
31 improvements in disease activity are appreciated. With a longer follow up it is possible that 
32 
33 combination cDMARD and methotrexate therapy would have associated with improved 
34 
35 
36 outcomes, with a reduction in the efficacious effect of glucocorticoids due to adverse effect 
37 
38 burden. A key determinant of glucocorticoid adverse effects and course length is the route of 
39 
40 
41 administration, with those commenced on oral glucocorticoids more likely to be exposed to 
42 
43 higher doses and more adverse effects as a result. The route of glucocorticoid administration 
44 
45 
was not collected as part of the national audit, so cannot be commented on further here. 
47 
48 However, given the importance of achieving low disease activity as rapidly as possible(23), 
49 




The national audit relied on clinician goodwill for data collection and case ascertainment. It is 
55 
56 likely that there was incomplete case capture and a skew towards departments with sufficient 
57 
58 staffing and infrastructure to assist with data collection. It is possible that prescribing 
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3 variation is wider than we have reported. Within the patients recruited, there was a high 
4 
5 
6 degree of incomplete data, particularly follow up DAS-28. This was handled using MI and NRI 
7 
8 approaches, with consistency in the findings. The proportion of missing follow up DAS-28 data 
9 
10 
11 varied between departments but was not predictive of DAS-28 response in sensitivity 
12 
13 analyses. Despite these mitigations, the proportions of missing outcome data are a limitation 
14 
15 






22 Despite much work on clinical guidelines, clinicians still vary enormously in their practice 
23 
24 
25 when managing RA. In the real-world setting, such decisions do appear to correlate with 
26 
27 clinical outcome. Early use of steroids predicts a better chance of EULAR DAS response. In 
28 
29 
contrast the selection of cDMARD strategy appeared not to predict response. 
31 
32 
33 New therapies licensed for RA over the next decade will bring incremental benefits to patients 
34 
35 at a high economic cost. Understanding how we can ensure optimal care across healthcare 
36 
37 
systems using existing therapies offers a simple and cost-effective alternative to improve 
39 
40 patient care. 
41 
42 




JG has received honoraria from Abbvie, Celgene, Janssen, Pfizer, and UCB; MY has received 
48 







56 This work was supported by The British Society for Rheumatology and Versus Arthritis, who 
57 
58 fund MYs’ salary. 
Rheumatology Page 14 of 31 















7 The authors would like to acknowledge the contribution of Dr Neil Snowden to the National 
8 














23 1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment 
24 strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised 
25 controlled trial. Lancet (London, England). 2004;364(9430):263-9. 
26 2. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician 
27 preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease 
28 activity. Arthritis care & research. 2010;62(1):101-7. 
30 3. NICE. Rheumatoid arthritis in adults: management 2018 [Available from: 
31 https://www.nice.org.uk/guidance/NG100. 
32 4. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR 
33 recommendations for the management of rheumatoid arthritis with synthetic and biological disease- 
34 modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017;76(6):960-77. 
35 5. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American 
36 College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 37 
2016;68(1):1-26. 
38 
39 6. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, et al. Efficacy of 
40 glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a 
41 systematic literature review informing the 2016 update of the EULAR recommendations for the 
42 
management of rheumatoid arthritis. Annals of the rheumatic diseases. 2017;76(6):1102-7. 
43 7. Ding C-Z, Yao Y, Feng X-B, Fang Y, Zhao C, Wang Y. Clinical analysis of chinese patients with 
44 rheumatoid arthritis treated with leflunomide and methotrexate combined with different dosages of 
45 glucocorticoid. Current therapeutic research, clinical and experimental. 2012;73(4-5):123-33. 
46 8. NICE. Rheumatoid arthritis in adults: diagnosis and management. Evidence review H 
7 Glucocorticoids 2018 [Available from: https://www.nice.org.uk/guidance/ng100/evidence/evidence- 
49 review-h-glucocorticoids-pdf-4903172325. 
50 9. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease 
51 activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 
52 1993;20(3):579-81. 
53 10. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum 
54 Dis Clin North Am. 2009;35(4):745-57, vii-viii. 
55 11. Pisati M. SPMAP: Stata module to visualize spatial data. Statistical Software Components: 
56 Boston College Department of Economics; 2007. 
58 12. Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, et al. Three out of four 
59 disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease 
Page 15 of 31 Rheumatology 










3 Activity Score remission at 12 months: results from the FIN-ERA cohort. Scandinavian Journal of 
4 Rheumatology. 2017;46(6):425-31. 
5 
13. Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blafield H, Ilva K, et al. Physicians' 
7 adherence to tight control treatment strategy and combination DMARD therapy are additively 
8 important for reaching remission and maintaining working ability in early rheumatoid arthritis: a 
9 subanalysis of the FIN-RACo trial. Annals of the rheumatic diseases. 2014;73(4):788-90. 
10 14. Garrood T, Shattles W, Scott DL. Treating early rheumatoid arthritis intensively: current UK 
11 practice does not reflect guidelines. Clin Rheumatol. 2011;30(1):103-6. 
12 15. Edwards CJ, Campbell J, van Staa T, Arden NK. Regional and temporal variation in the 
13 treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study. 
14 
2012;2(6):e001603. 
16 16. Ferraz-Amaro I, Seoane-Mato D, Sanchez-Alonso F, Martin-Martinez MA. Synthetic disease- 
17 modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a 
18 cross-sectional national study. Rheumatol Int. 2015;35(11):1825-36. 
19 17. Kim SC, Yelin E, Tonner C, Solomon DH. Changes in use of disease-modifying antirheumatic 
20 drugs for rheumatoid arthritis in the United States during 1983-2009. Arthritis Care Res (Hoboken). 
21 2013;65(9):1529-33. 
22 18. Crane MM, Juneja M, Allen J, Kurrasch RH, Chu ME, Quattrocchi E, et al. Epidemiology and 
23 Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population. Arthritis 
24 
25 Care Res (Hoboken). 2015;67(12):1646-55. 
26 19. Nam JL, Villeneuve E, Hensor EMA, Conaghan PG, Keen HI, Buch MH, et al. Remission 
27 induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a 
28 double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the 
29 IDEA study). Annals of the rheumatic diseases. 2014;73(1):75-85. 
30 20. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I, et al. Low-dose 
31 prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early 
32 active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year 
33 randomized trial. Arthritis & Rheumatism. 2005;52(11):3360-70. 
35 21. Ruyssen-Witrand A, Constantin A. Controversies in rheumatoid arthritis glucocorticoid 
36 therapy. Joint Bone Spine. 2018;85(4):417-22. 
37 22. Burmester G-R, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and 
38 safety of ascending methotrexate dose in combination with adalimumab: the randomised 
39 CONCERTO trial. Annals of the rheumatic diseases. 2015;74(6):1037-44. 
40 23. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Peeters AJ, van Krugten 
41 MV, Breedveld FC, et al. Probability of continued low disease activity in patients with recent onset 
42 rheumatoid arthritis treated according to the disease activity score. Annals of the rheumatic 43 














Rheumatology Page 16 of 31 

























20 Table 1. Baseline characteristics, quality of care, and therapy choices for all patients 
21 
22 





































N = 7154 Number Missing (%) 
Age, mean (SD) 58 2 (15.2) 39 (0.5) 
 
Female, % 63.5 39 (0.5) 
IMD rank, median (Q1, Q3) 645 (303 to 1035) 814 (11.4) 
White European, % 90.8 1095 (15.3) 
Current smoker, % 22.1 1334 (18.6) 
Full time paid employment, % 39.4 1429 (20.0) 
Seropositive, % 78.1 1874 (26.2) 
Baseline DAS-28, mean (SD) 5.1 (1.4) 2477 (34.6) 
Follow up DAS-28, mean (SD) 3.5 (1.5) 4485 (62.5) 
Rheumatology Departments 136 0 
Symptom duration in days, median 
(Q1, Q3) 
102 (52 to 218) 0 
Referral within 3 days, % 16.7 0 
Review within 21 days, % 38.0 68 (1.0) 
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15 Patients who were positive for RF and/or anti-CCP were considered seropositive. cDMARD = conventional 









































57 Patients who were positive for RF and/or anti-CCP were considered seropositive. 
Treatment within 90 days, % 60.1 935 (13.1) 
Baseline Therapy 
cDMARD combination therapy, % 39.9 1603 (22.4) 
Glucocorticoid therapy, % 80.0 126 (1.8) 
Methotrexate therapy, % 73.9 1482 (20.7) 
 
 Achieved moderate or no 
EULAR DAS response 
Achieved good EULAR DAS 
response 
p value 
 (N = 1378) (N = 878)  
Age, mean (SD) 59.1 (14.2) 59.7 (14.6) 0.37 
Female 915 (67.0%) 530 (60.6%) 0.002 
IMD rank, median (Q1, Q3) 626 (301, 1046) 668 (326, 1006) 0.52 
White European 1132 (91.0%) 714 (92.0%) 0.43 
Current smoker 298 (25.0%) 167 (22.2%) 0.16 
Full time paid employment 448 (38.3%) 264 (35.8%) 0.27 
Seropositive 937 (83.7%) 605 (85.1%) 0.44 
Symptom duration in days, 
median (Q1, Q3) 
103 (53, 225) 89 (50, 75) 0.0013 
Referral letter states EIA 1256 (91.2%) 798 (90.9%) 0.83 
Referral within 3 days 207 (15.0%) 139 (15.8%) 0.60 
Review within 21 days 508 (36.9%) 392 (44.6%) <0.0001 
Treatment within 90 days 844 (68.7%) 546 (72.1%) 0.11 
 





























































56 Further detail on propensity and imputation models are in the supplementary material, available at 
57 
58 
Rheumatology online. Adjustment for age, gender, ethnicity, smoking status, work status, index of multiple 
59 
deprivation, referral time, rheumatology review time, antibody status, and symptom duration. The department 
60 
where treatment took place was included as a random effect in all models. 
Good EULAR DAS-28 
response 
Odds Ratio 95% confidence interval p value 
Monotherapy and combination therapy (monotherapy = reference) 
Unadjusted (N = 1,921) 0.93 0.76 to 1.14 0.50 
Adjusted (N = 1,037) 1.02 0.77 to 1.34 0.91 
Propensity (N = 1,037) 0.93 0.62 to 1.39 0.72 
Multiple Imputation 1.05 0.90 to 1.23 0.52 
Methotrexate therapy (no methotrexate therapy = reference) 
Unadjusted (N = 1,945) 0.89 0.71 to 1.13 0.36 
Adjusted (N = 1,050) 0.88 0.64 to 1.22 0.45 
Propensity (N = 1,045) 0.89 0.59 to 1.34 0.59 
Multiple Imputation 0.99 0.80 to 1.22 0.92 
Glucocorticoid therapy (no glucocorticoid therapy = reference) 
Unadjusted (N = 2,242) 1.63 1.23 to 2.15 0.001 
Adjusted (N = 1,211) 1.93 1.31 to 2.84 0.001 
Propensity (N = 1,211) 2.01 1.31 to 3.11 0.002 
Multiple Imputation 1.63 1.36 to 1.96 <0.001 
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3 Figure legends 
4 
5 
Figure 1. Caterpillar plots of combination cDMARD, methotrexate, glucocorticoid prescribing by 
7 department. (1a) combination cDMARD, (1b) methotrexate, (1c) glucocorticoid prescribing by 
8 department. 
9 
10 Figure  2.  Heat  maps  of  combination  cDMARD,  methotrexate,  glucocorticoid  prescribing  by 

































































































40 Figure 1. Caterpillar plots of (1a) combination cDMARD, (1b) methotrexate, and (1c) glucocorticoid 
41 prescribing by department. The gray markers are the departmental proportions of prescribing (the number 
prescribed a given drug as a proportion of patients seen in that department). The blue markers are the 
predicted random departmental effect on prescribing from the mixed effects models, with 95% confidence 
43 intervals in red. The black horizontal line represents the overall mean. 
44 



































































42  Heat maps of combination cDMARDs (2a), methotrexate (2b), and glucocorticoids (2c) prescribing across 
England and Wales, with a zoomed in view of Greater London. Prescribing varied widely across England and 
44 
Wales, with no clear regional patterns 






















3 SUPPLEMENTARY MATERIAL 
4 
5 Propensity modelling. 
6 
7 Baseline patient covariates, determined a priori, were included in three logistic regression 
8 
9 models to predict three baseline treatment choices: 
10  DMARD monotherapy vs DMARD combination therapy; 
12  methotrexate vs no methotrexate; 
13  glucocorticoid therapy vs no glucocorticoid therapy. 
14 
15 The models were used to calculate propensity scores for each patient. The propensity score 
16 
17 model included age, sex, ethnicity, smoking status, work status, SEP, autoimmune antibody 
18 status, and symptom duration. On assessment of the model, the inverse of the probability 
19 performed the best across the three treatment choices when comparing standardised 
20 
21 differences. The tables below detail the weighted means and standardised means, before and 
22 after propensity model weighting. 
23 
24 Supplementary Table S1A: Propensity modelling for DMARD monotherapy vs DMARD 




































Before weighting    






age 57.24 57.84 -0.042 
proportion male 0.36 0.38 -0.031 
proportion white 0.92 0.91 0.033 
proportion smokers 0.24 0.26 -0.037 
proportion in paid work 0.42 0.38 0.08 
deprivation quintile 3.1 3.03 0.05 
proportion autoantibody 
positive 
0.8 0.78 0.058 
symptom duration (days) 231.79 294.62 -0.097 
After weighting    
age 57.58 57.6 -0.002 
proportion male 0.37 0.37 -0.003 
proportion white 0.91 0.91 0 
proportion smokers 0.25 0.25 0.001 
proportion in paid work 0.4 0.4 -0.002 
deprivation quintile 3.05 3.05 -0.001 
proportion autoantibody 
positive 
0.79 0.79 0.001 








































































age 57.83 57.15 0.046 
proportion male 0.37 0.36 0.037 
proportion white 0.92 0.88 0.138 
proportion smokers 0.24 0.26 -0.042 
proportion in paid work 0.41 0.37 0.078 
deprivation quintile 3.06 3.04 0.013 
proportion autoantibody 
positive 
0.78 0.8 -0.048 
symptom duration (days) 253.38 309.93 -0.082 
After weighting    
age 57.66 57.68 -0.002 
proportion male 0.37 0.37 0.001 
proportion white 0.91 0.91 0.001 
proportion smokers 0.25 0.25 0.001 
proportion in paid work 0.4 0.4 0.003 
deprivation quintile 3.05 3.05 0.002 
proportion autoantibody 
positive 
0.79 0.79 -0.007 







3 Supplementary Table 1C: Propensity modelling for glucocorticoid therapy vs no 
4 































































age 58.3 55.01 0.223 
proportion male 0.37 0.35 0.042 
proportion white 0.91 0.86 0.159 
proportion smokers 0.24 0.23 0.023 
proportion in paid work 0.38 0.45 -0.142 
deprivation quintile 3.04 3.06 -0.011 
proportion autoantibody 
positive 
0.78 0.78 -0.005 
symptom duration (days) 251.84 345.66 -0.134 
After weighting    
age 57.66 57.66 0 
proportion male 0.37 0.36 0.007 
proportion white 0.9 0.9 0.003 
proportion smokers 0.24 0.25 -0.014 
proportion in paid work 0.39 0.39 0.001 
deprivation quintile 3.05 3.04 0.005 
proportion autoantibody 
positive 
0.78 0.79 -0.015 








3 Handling missing data 
4 
5 There were high levels of missing data, detailed in table 1 of the paper. A breakdown of 
6 
7 demographic differences between those with and without complete DAS-28 outcome data is 
8 detailed in table 2. Two approaches were taken to account for this: (1) Non responder 




13 Supplementary Table S2: Patient demographics stratified by those with complete and 














































 Complete DAS-28 data at 
baseline and follow up 
Incomplete DAS-28 data 
at baseline or follow up 
p values 
 (N = 2256) (N = 4898)  
Age, mean (SD) 59.3 (14.4) 57.6 (15.6) <0.0001 
Female 64.5% 63.4% 0.37 
IMD rank, median (Q1, Q3) 626 (297, 1016) 640 (300, 1022) 0.69 
White European 91.4% 90.5% 0.24 
Current Smoker 24.0% 21.2% 0.017 
Full time paid employment 37.3% 40.4% 0.026 
Seropositive 84.3% 74.8% <0.0001 
DAS-28 at baseline, mean (SD) 5.2 (1.3) 4.9 (1.4) <0.0001 
Symptom duration in days, 
median (Q1, Q3) 

































































Good EULAR DAS-28 
response 
Odds Ratio 95% confidence interval p value 
Monotherapy and combination therapy (monotherapy = reference) 
Adjusted 1.14 0.90 to 1.46 0.3 
Methotrexate therapy (no methotrexate therapy = reference) 
Adjusted 1.24 0.95 to 1.64 0.1 
Glucocorticoid therapy (no glucocorticoid therapy = reference) 
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